Development of Autonomous Glycemic Control Mechanism for Patients Suffering Glycemic Abnormalities as a Result of Critical Illnesses

Develop mechanical or biologically engineered solutions to revolutionize reliable, autonomous, multi-hormonal glycemic control to improve patient outcomes stemming from traumatic organ injury and loss, critical illness, and long-term therapeutic maintenance.

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21 Clinical Trial Not Allowed) -

This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushing’s diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases.

Mechanisms Underlying the Contribution of Type 1 Diabetes Disease-associated Variants (R01 Clinical Trial Not Allowed) - December 6, 2018

This Funding Opportunity Announcement (FOA) encourages applications from integrative teams and individual investigators for projects to determine the mechanisms underlying the contribution of these risk-associated genes and their variants for Type 1 Diabetes
(T1D).

Administrative Supplements to Existing NIH Grants and Cooperative Agreements

The National Institutes of Health (NIH) hereby notify Program Directors/Principal Investigators (PD(s)/PI(s)) holding specific types of NIH research grants listed in the full Funding Opportunity Announcement (FOA) that funds may be available for administrative supplements to meet increased costs that are within the scope of the approved award, but were unforeseen when the new or renewal application or grant progress report for non-competing continuation support was submitted. 

JDRF Canadian Clinical Trial Network (CCTN) FY18 Postdoctoral Fellowship in Clinical Translation in T1D Program - March 27, 2018

JDRF Canadian Clinical Trial Network (JDRF CCTN) is pleased to announce that Eli Lilly Canada Inc. has provided $120,000 in support of two CCTN Post-Doctoral Fellows for one year in the sum of $60,000 each.